HSA
HAE icon

Hussman Strategic Advisors’s Haemonetics HAE Stock Holding History

Hussman Strategic Advisors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,500
Closed -$592K – 270
2026
Q1 		$592K Buy
+10,500
New +$684K 0.13% 234
2025
Q4 		– Sell
-10,500
Closed -$512K – 305
2025
Q3 		$512K Buy
+10,500
New +$650K 0.11% 240

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hussman Strategic Advisors's HAE Position: Q2 2026 in Review

Hussman Strategic Advisors sold out of Haemonetics (HAE) in Q2 2026, closing a stake of 10,500 shares — an estimated $592K sold.

Hussman Strategic Advisors first reported a position in HAE in Q3 2025 and held it in 2 quarters. The position peaked at $592K in Q1 2026. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Hussman Strategic Advisors reported no remaining Haemonetics position as of Q2 2026 after selling out during the quarter.
  • Hussman Strategic Advisors sold 10,500 Haemonetics shares in Q2 2026, an estimated $592K.
  • Hussman Strategic Advisors first reported a position in Haemonetics in Q3 2025 and held it in 2 quarters.
  • Hussman Strategic Advisors's Haemonetics position peaked at $592K in Q1 2026.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.